Blockchain Registration Transaction Record

BRAIN Biotech Secures Key Patent for Broad-Spectrum CRISPR Genome Editing Tech

BRAIN Biotech gains European patent for CRISPR-BMC nuclease, a broad-spectrum genome-editing tool for optimizing industrial microbial production strains.

This news matters because it represents a tangible advancement in the democratization and application of CRISPR technology beyond human therapeutics. While much public attention focuses on medical uses, this patent strengthens the toolkit for industrial biotechnology, a field critical to developing more sustainable manufacturing processes. By enabling precise, efficient editing of a wide array of microorganisms—from common workhorses like E. coli and yeast to fungi and plants—this technology can accelerate the development of optimized microbial 'factories.' This has direct implications for producing everything from biofuels and biodegradable plastics to food ingredients and pharmaceuticals in a more efficient, cost-effective, and potentially greener manner. The expansion of licensing activities means this tool could soon be deployed across multiple industries, potentially lowering costs and increasing the scalability of bio-based products, which contributes to a broader transition toward a bioeconomy less reliant on petrochemicals.